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Abstract: Background: Uremic toxins have emerged as potential mediators of morbidity and mortality
in patients with chronic kidney disease (CKD). Indole-3-acetic acid (IAA, a tryptophan-derived
uremic toxin) might be a useful biomarker in patients with CKD. The objectives of the present study
were to (i) describe IAA concentrations in a cohort of non-transplanted patients with CKD and a
cohort of transplanted patients with CKD, and (ii) investigate the possible relationship between IAA
levels and adverse outcomes in the two cohorts. Methods: Levels of free and total IAA were assayed
in the two prospective CKD cohorts (140 non-transplanted patients and 311 transplanted patients).
Cox multivariate analyses were used to evaluate the association between IAA levels and outcomes
(mortality, cardiovascular events, and graft loss). Results: In the non-transplanted CKD cohort,
free and total IAA increased progressively with the CKD stage. In the transplanted CKD cohort,
free and total IAA levels were elevated at the time of transplantation but had fallen substantially
at one-month post-transplantation. Indole acetic acid concentrations were lower in transplanted
patients than non-dialysis non-transplanted patients matched for estimated glomerular filtration
rate (eGFR), age, and sex. After adjustment for multiple confounders, the free IAA level predicted
overall mortality and cardiovascular events in the non-transplanted CKD cohort (hazard ratio [95%
confidence interval]: 2.5 [1.2–5.1] and 2.5 [1.3–4.8], respectively). In the transplanted CKD cohort,
however, no associations were found between free or total IAA on one hand, and mortality, CV event,
or graft survival on the other. Conclusion: We demonstrated that levels of IAA increase with the CKD
stage, and fall substantially, even normalizing, after kidney transplantation. Free IAA appears to be
a valuable outcome-associated biomarker in non-transplanted patients, but—at least in our study
setting—not in transplanted patients.
Keywords: uremic toxins; chronic kidney disease; indole acetic acid; kidney transplantation;
patient outcome
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1. Introduction
Patients with chronic kidney disease (CKD) suffer from several metabolic and enzymatic
impairments, which result in high morbidity and mortality rates [1]. As kidney function declines,
various compounds accumulate progressively. Many of these solutes affect biologic functions and
contribute to uremic syndrome, and they are referred to as uremic toxins [2].
The gut microbiota has an important role in the generation of precursors of specific uremic toxins
associated with poor outcomes in patients with CKD [3]. Both indoxyl sulfate (IS) and indole-3-acetic
acid (IAA) originate in the colon, where tryptophan is metabolized by gut bacteria into indole and
IAA. Various reports have shown that the accumulation of these uremic toxins in CKD are associated
with a decline in kidney function and adverse outcomes [4,5]. However, there are fewer preclinical
and clinical data on IAA [5] than on IS [4,6].
Several explanations for the potential toxicity of tryptophan-derived uremic toxins have been
put forward, including the activation of inflammation and coagulation pathways [6,7]. Indeed,
tryptophan-derived uremic toxins are agonists of the aryl hydrocarbon receptor (AhR) complex. The
accumulation of tryptophan-derived indole uremic toxins in patients with CKD may persistently
activate the AhR [8], leading to pro-oxidant, pro-inflammatory, pro-coagulant, and pro-apoptotic
effects [5].
Most of the clinical data on tryptophan-derived uremic toxins were collected in predialysis or
dialyzed patients with CKD. Few studies have evaluated these toxins in transplanted patients with
CKD, and no data on IAA are available [9–11].
Hence, the objectives of the present study were to (i) describe IAA concentrations in transplanted
vs. non-transplanted patients with CKD, and (ii) investigate the putative relationship between IAA
concentrations and adverse outcomes.
2. Results
2.1. Levels of IAA
The characteristics of the study cohorts are summarized in Table 1. In the cohort of 140
non-transplanted patients with CKD, the free and total IAA increased progressively with the CKD
stage, with the highest concentrations in dialyzed patients (Figures 1 and 2). In the cohort of 311
transplanted patients with CKD, the free and total IAA levels were high at the time of transplantation
but fell substantially and significantly at one-month post-transplantation and then remained low at
12-months post-transplantation (Figures 1 and 2). After matching 45 patients in the transplanted cohort
and 45 non-dialysis patients in the non-transplanted cohort for estimated glomerular filtration rate
(eGFR) (mean eGFR = 36 ± 11) and age (mean age = 68 ± 11), we found that mean levels of free and
total IAA were significantly lower in transplanted patients (one-month post-transplantation) than in
non-transplanted patients (respectively, 0.028 ± 0.007 mg/dL vs. 0.009 ± 0.006 mg/dL for free IAA
(p < 0.0001) and 0.092 ± 0.042 mg/dL vs. 0.067 ± 0.056 mg/dL for total IAA (p = 0.020)) (Figure 3A,B).
Table 1. Characteristics of the study cohorts.
Patient Characteristics Non-Transplanted CKD Cohort(n = 140)
Transplanted Cohort
(n = 311)
Age, years 67 ± 12 56 ± 14
Males, % 60 61.8
Diabetes mellitus, % 42 9
Hypertension, % 90 69
Dyslipidemia, % 60 22
History of cardiovascular disease, % 31 23
Active smoker, % 41 17
Body mass index (kg/m2) 28 ± 6 25 ± 5
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Table 1. Cont.
Patient Characteristics Non-Transplanted CKD Cohort(n = 140)
Transplanted Cohort
(n = 311)
Calcium, mmol/L 2.3 ± 0.2 2.3 ± 0.2
Phosphate, mmol/L 1.3 ± 0.4 0.9 ± 0.5
Proteins, g/L 55.2 ± 6.9 69.0 ± 7.0
Free IAA, mg/dL 0.04 ± 0.03 0.19 ± 0.1
Total IAA, mg/dL 0.12 ± 0.08 2.4 ± 1.1
For the transplanted cohort, the data presented here were collected at the time of transplantation.
Figure 1. Serum levels of free indole acetic acid in a non-transplanted chronic kidney disease (CKD)
cohort and a transplanted cohort.
Boxplot with whiskers with maximum 1.5 interquartile range.
Figure 2. Serum levels of total indole acetic acid in a non-transplanted CKD cohort and a
transplanted cohort.
Boxplot with whiskers with maximum 1.5 interquartile range.
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Figure 3. Comparison of mean (range) serum free (a) and total (b) indole-3-acetic acid (IAA) levels in
non-dialized non-transplanted patients with CKD and in transplant recipients at month one (36.0 ±
10.4 mL/mi,/1.73 m2) matched for age, sex and estimated glomerular filtration rate (eGFR). (a) * p< 0.0001;
(b) * p = 0.02. Boxplot with whiskers with maximum 1.5 interquartile range.
2.2. Non-Transplanted Patients with CKD
During the follow-up period (mean duration: 32 ± 12 months), 44 patients died (20 predialysis
patients and 24 hemodialyzed patients) and 48 had at least one cardiovascular event. In the study
population as a whole, patients with above-median free and total IAA concentrations had a significantly
higher risk of overall mortality than patients with below-median levels (p = 0.001 for free IAA and
p = 0.003 for total IAA). Tables 2 and 3 summarized the results of the Cox regression analyses for
the entire population. The free IAA level was still an independent predictor of overall mortality and
cardiovascular events after adjustment for multiple confounders (age, dialysis status, CRP, serum
albumin, and a history of cardiovascular disease) but total IAA level was not (Table 2).
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Table 2. A Cox proportional hazards analysis of plasma free and total IAA levels (stratified by the
median) for predicting (A) all-cause mortality and (B) cardiovascular events in the non-transplanted
CKD cohort (n = 140).
A
Models Free IAA Total IAA
HR [95%CI] p HR [95%CI] p
Unadjusted 3.1 [1.6–6.2] 0.001 2.7 [1.4–5.2] 0.003
+age 3.4 [1.7–6.8] <0.0001 2.9 [1.5–5.5] 0.001
+age + CRP + hemoglobin 2.3 [1.1–4.9] 0.027 2.9 [1.5–5.5] 0.002
+age + CRP + albumin 2.3 [1.1–4.9] 0.027 2.5 [1.3–4.7] 0.007
+age+ CRP + dialysis 2.5 [1.2–5.1] 0.017 2.0 [0.9–4.1] 0.070
B
Models Free IAA Total IAA
HR [95%CI] p HR [95%CI] p
Unadjusted 2.3 [1.3–4.3] 0.006 1.3 [0.7–2.3] 0.378
+age 2.5 [1.4–4.7] 0.002 1.3 [0.8–2.4] 0.322
+age + CRP + hemoglobin 2.5 [1.3–4.6] 0.031 1.3 [0.7–2.3] 0.298
+age + CRP + albumin 2.1 [1.1–3.9] 0.016 1.1 [0.6–2.1] 0.612
+age + CRP+ history of cardiovascular disease 2.5 [1.3–4.6] 0.004 1.3 [0.7–2.3] 0.365
+age + CRP +dialysis 2.5 [1.3–4.8] 0.004 1.1 [0.6–2.2] 0.639
HR = hazard ratio summarizing the effect of above- and below-median levels of IAA (i.e., free IAA > 0.0285 mg/dl
vs. with ≤0.0285 mg/dl, and total IAA > 0.101 mg/dl vs. ≤0.101 mg/dl) on the overall mortality risk in an unadjusted
model and in models adjusted for the covariates mentioned.
Table 3. A Cox proportional hazards analysis of plasma free and total IAA levels at the time of
transplantation time (stratified by the median) in predicting (A) all-cause mortality, (B) cardiovascular
events and (C) graft loss in the transplanted cohort (n = 311).
A
Models Free IAA (T0) Total IAA (T0)
HR [95%CI] p HR [95%CI] p
Unadjusted 1.0 [0.6–1.8] 0.980 0.8 [0.5–1.5] 0.841
+age 0.8 [0.4–1.4] 0.394 0.9 [0.5–1.6] 0.698
+age + history of cardiovascular disease 1.2 [0.6–2.4] 0.629 1.3 [0.6–2.5] 0.511
+age + history of cardiovascular disease +
years on dialysis 1.1 [0.6–2.3] 0.700 1.2 [0.6–2.4] 0.587
B
Models Free IAA (T0) Total IAA (T0)
HR [95%CI] p HR [95%CI] p
Unadjusted 1.4 [0.8–2.5] 0.185 1.4 [0.8–2.4] 0.244
+age 1.2 [0.7–2.2] 0.412 1.5 [0.8–2.5] 0.167
+age + history of cardiovascular disease 1.2 [0.6–2.3] 0.634 1.2 [0.6–2.3] 0.610
+age + history of cardiovascular disease +
years on dialysis 1.2 [0.6–2.4] 0.517 1.3 [0.7–2.5] 0.478
C
Models Free IAA (T0) Total IAA (T0)
HR [95%CI] p HR [95%CI] p
Unadjusted 1.2 [0.7–2.0] 0.569 0.9 [0.5–1.5] 0.570
+age 1.3 [0.7–2.2] 0.378 0.9 [0.5–1.5] 0.609
+age +years on dialysis 1.3 [0.8–2.2] 0.363 1.3 [0.5–1.5] 0.621
H R = hazard ratio summarizing the effect of above- and below-median levels of IAA (i.e., free IAA >0.034 mg/dl vs.
≤0.034 mg/dl, and total IAA >0.149 mg/dl vs. ≤0.149 mg/dl) on the overall mortality risk in an unadjusted model
and in models adjusted for the covariates mentioned.
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2.3. Transplanted Patients
During the follow-up period (mean duration: 113 ± 29 months), there were 55 deaths, 70
cardiovascular events, and 71 graft losses. Non-adjusted and adjusted models failed to show
associations between free and total IAA at the time of transplantation on one hand, and mortality, CV
events, or graft survival on the other (Table 3). The same results were obtained when total and free
IAA were analyzed 1- and 12-months post-transplantation (data not shown).
3. Discussion
In the present study, we measured IAA concentrations, a protein-bound uremic toxin that originates
from microbiota metabolism of amino acids and activates the AhR complex, in non-transplanted and
transplanted patients with CKD. Our key findings were that (i) in non-transplanted patients, levels of
IAA were abnormally high and increased with the CKD stage, (ii) IAA levels fell substantially and
significantly within a month of kidney transplantation and remained low after one year, (iii) total and
free IAA levels were significantly lower in transplant recipients than in non-recipients matched for
age, sex, and eGFR, and (iv) a high free IAA level was an independent risk factor for overall mortality
in non-transplanted patients with CKD, whereas free and total IAA levels were not associated with
adverse outcomes in patients having received a kidney transplant.
We first observed, in the non-transplanted cohort, that free and total IAA levels changed in a similar
way to other protein-bound uremic toxins [4,12,13], i.e., with a progressive increase as the eGFR declined,
and the highest levels in dialyzed patients. Next, levels of free and total IAA decreased substantially
following kidney transplantation and were lower in kidney transplant recipients than in eGFR-matched
patients with CKD. Hence, the change in IAA levels after kidney transplantation was similar to the one
seen for other colonic-microbiota-derived uremic retention solutes such as IS, p-cresyl sulfate (PCS),
p-cresyl glucuronide, trimethylamine N-oxide, and phenylacetylglutamine [10,11]. There are several
possible explanations for the lower levels of uremic toxins measured in kidney transplant recipients,
relative to non-transplanted patients with CKD. Firstly, the microbiota might be modified by the
transplantation procedure itself or the drugs given after transplantation (such as immunosuppressants
and antibiotics) [14]. Indeed, it was previously reported that antimicrobial therapy is likely to alter the
composition of the gut microbiota and thus modifies uremic toxin generation [14]. In recent years,
many animal and human studies have indicated that gut microbial dysbiosis is closely linked to
allogenic transplantation in general (i.e., including kidney transplantation) and post-transplantation
complications in particular [15]. Many transplant recipients receive antibiotics and there is a growing
body of evidence to show that antibiotic treatment modifies the colonic microbiota and thus microbial
metabolism [16].
In recent years, it has been increasingly suspected that the metabolism of the colonic microbiota
contributes to the accumulation of uremic retention solutes in CKD (especially IS and PCS). Although
both solutes have been linked to adverse outcomes in patients with kidney dysfunction [4,12,13], less
attention has been paid to IAA [5]. Dou et al. showed in a cohort of 120 patients at different CKD stages
that mortality and cardiovascular events were significantly more frequent in patients with higher levels
of IAA [5]. We confirmed these results in a similar cohort. However, we failed to show an association
between adverse outcomes in transplanted patients on one hand and IAA levels (regardless of the
sample time post-transplantation) on the other.
There are several possible explanations for the positive, independent association between free
IAA levels and adverse outcomes in non-transplanted patients with CKD. As for IS, these effects might
primarily be related to the activation of the AhR, which appears to have a central role in the biological
action of several indoles [17]. High levels of IAA might constitutively activate the AhR and thus lead
to pro-oxidant, pro-inflammatory, pro-coagulant, and/or pro-apoptotic effects on the cardiovascular
system [17,18].
In patients with CKD who received a kidney transplant, it appears that post-transplantation
adverse events were influenced by factors other than the level of IAA—as we previously observed
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for IS. This finding could be related to the normalization of IAA levels. In addition, in comparison
to non-transplanted patients with CKD, kidney transplanted patients presented an increased risk of
malignancy-related death and of infectious death that is not likely linked to uremic toxins.
The present study’s main strengths are the assessment of levels of IAA in two CKD cohorts,
and the analysis of hard outcomes. In contrast, the main study limitation was the single-center
design that nevertheless enabled us to standardize the assays and patient care. Furthermore, a
lack of power prevented us from evaluating the impact of IAA on the progression of CKD in the
non-transplanted cohort.
In conclusion, our results confirmed that levels of IAA increased in parallel with CKD progression
and that kidney transplantation led to a substantial decrease and even normalization in these levels.
Free IAA appears to be a valuable biomarker in non-transplanted patients but—at least in our study
setting—not in transplanted patients.
4. Methods
4.1. Study Population
Patients with CKD were recruited into two previously described observational cohort
studies [10,19] at Amiens University Medical Center (Amiens, France). All the patients gave their
written, informed consent for participation. Both study protocols were approved by the local
investigational review board ([PHRC local number: 2006/ 0100 (27/03/2006)], Comité de Protection des
Personnes Nord-Ouest II, Amiens, France).
4.2. The Transplanted Cohort
Over a 7-year period (from 1 January 1998 to 31 December 2005), a total of 311 patients had a
kidney transplantation in the Department of Nephrology, Dialysis and Transplantation at Amiens
University Medical Center, and were included in the TOXTRANSLANT study. The included patients
consented to blood sample collection at the various study time points: before kidney transplantation
(T0) and 1 and 12 months afterwards (M1 and M12). At each study visit, demographic, clinical,
laboratory, and treatment-related data were recorded on the basis of the patients’ medical charts.
Previous cardiovascular disease was defined as a history of any of the following events: myocardial
infarction, stroke, heart failure, angina pectoris, surgical procedures for angina, or coronary/peripheral
artery disease (including percutaneous transluminal angioplasty). For descriptive purposes, patients
who reported active or historical use of insulin and/or orally administered hypoglycemic drugs were
considered to be diabetic. The patients were followed prospectively for death, CV outcomes, and
graft loss until 30 September 2011. For deaths, the patient’s medical records were reviewed by a
physician and the cause of death was assigned on the basis of all the available clinical information. For
out-of-hospital deaths, the patient’s primary care physician was interviewed for relevant information.
Cardiovascular events were defined as cardiovascular death or any adverse event directly related
to a cardiovascular system dysfunction (stroke, angina pectoris/myocardial infarction, congestive
cardiac failure, peripheral ischemia, or new-onset arrhythmia) or surgical procedures for angina or
coronary/peripheral arterial disease. Graft loss in transplant recipients was defined as the need for
dialysis treatment (because of end-stage kidney disease) for at least 3 consecutive months.
4.3. CKD Cohort
Over an 18-month period (from January 2006 to June 2007), a total of 150 Caucasian prevalent
patients with CKD were recruited from the Nephrology Department’s outpatient clinic at Amiens
University Medical Center. Included patients had to be over the age of 40 with a confirmed diagnosis of
CKD. Stage 5D patients with CKD must have received thrice-weekly hemodialysis for at least 3 months.
The main exclusion criteria were the presence of chronic inflammatory disease, atrial fibrillation,
complete heart block, abdominal aorta aneurysm, aortic and/or femoral artery prosthesis, primary
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hyperparathyroidism, kidney transplantation, and any acute cardiovascular event in the 3 months
before screening for inclusion. The 140 patients who met all the inclusion criteria and had available
serum IAA data were included in the analyses.
All patients were day-hospitalized for collection of a blood sample and an interview. Hemodialyzed
patients were seen on a dialysis-free day or the morning before their dialysis session, if possible. The
patient interview focused on comorbidities and the personal medical history. The patients’ medical
charts were reviewed, in order to identify and record any concomitant medications. For descriptive
purposes, patients who reported current or previous use of insulin and/or orally administered
hypoglycemic drugs were considered to be diabetic. Previous cardiovascular disease was defined
as a history of any of the following events: myocardial infarction, stroke, heart failure, angina
pectoris, surgical procedures for angina, or coronary/peripheral artery disease (including percutaneous
transluminal angioplasty). Cardiovascular events were defined as cardiovascular death or any adverse
event directly related to a cardiovascular system dysfunction (stroke, angina pectoris/myocardial
infarction, congestive cardiac failure, peripheral ischemia, or new-onset arrhythmia) or surgical
procedures for angina or coronary/peripheral arterial disease. Death records were established
prospectively. Each medical chart was reviewed, and the cause of death was assigned by a physician
on the basis of all the available clinical information. For out-of-hospital deaths, the patient’s family
doctor was interviewed to obtain pertinent information on the cause.
4.4. Laboratory Tests
In the non-transplanted cohort, blood samples were collected on the day of inclusion only. In the
transplanted cohort, blood samples were collected at three time points: immediately before kidney
transplantation (T0) and then 1- and 12-months afterwards (M1 and M12). An aliquot of each blood
sample was analyzed immediately in an on-site biochemistry and bone biology laboratory, and the
remainder was frozen and stored at −80 ◦C for subsequent quantification of IAA. Serum calcium,
phosphate, creatinine, and protein levels were assayed using standard auto-analyzer techniques
(the Modular system from Roche Diagnostics, Basel, Switzerland). Free and total levels of IAA
in samples from both transplanted and non-transplanted cohorts were measured by reverse-phase
high-performance liquid chromatography (HPLC) at the Nephrology Section of the Ghent University
Hospital (Ghent, Belgium). The frozen serum samples were thawed, deproteinized by heat denaturation,
and then IAA concentrations were quantified using HPLC and fluorescence detection, as described
previously [20]. Reference values for healthy subjects were 0.04 ± 0.02 mg/dL and 0.005 ± 0.002 mg/dL
for total IAA and free IAA, respectively.
4.5. Statistical Analysis
Data were expressed as the mean ± SD or the number (percentage), as appropriate. Levels of
IAA were compared using independent- or paired-sample tests, as appropriate. In the two cohorts,
univariate and multivariate analyses were performed using Cox proportional hazard models of
different outcomes. In the non-transplanted CKD cohort, the outcome was overall mortality. In the
transplanted cohort, the outcomes were overall mortality, CV events, and graft loss. For multivariate
models, adjustment variables were preselected (on the basis of a literature review) and analyzed in a
crude model. Variables with p > 0.10 in the crude model were excluded from the multivariate analyses.
Various multivariate models were applied for each outcome; the number of adjustment variables in
each model was limited by the outcome frequency. In all tests, the threshold for statistical significance
was set to p ≤ 0.05. Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL,
USA), version 18.0 for Windows (Microsoft Corp, Redmond, WA, USA).
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